Travere Therapeutics' (TVTX) Outperform Rating Reiterated at Evercore ISI
Evercore ISI restated their outperform rating on shares of Travere Therapeutics (NASDAQ:TVTX – Free Report) in a research note published on Tuesday morning, Benzinga reports. The brokerage currently has a $30.00 target price on the stock. TVTX has been the subject of several other reports. Canaccord Genuity Group reduced their target price on Travere Therapeutics […]